Yang Jia, Hu Man, Bai Xinbin, Ding Xingchen, Xie Li, Ma Ji, Fan Bingjie, Yu Jinming
Shandong Cancer Hospital affiliated to Shandong University.
Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences.
Medicine (Baltimore). 2019 Sep;98(39):e17231. doi: 10.1097/MD.0000000000017231.
Plasma levels of soluble PD-L1 (sPD-L1) have been reported to be an independent prognostic factor in many malignant tumors. The expression of sPD-L1 in nasopharyngeal carcinoma (NPC) has not been reported. The purpose of this study was to evaluate the expression of sPD-L1 and analyze its correlation with clinical characteristics in patients with NPC.Thirty-five patients with stage I-IVa NPC were included. Plasma samples were obtained pretreatment. The sPD-L1 concentrations were measured by enzyme-linked immunosorbent assay (ELISA). The correlations of sPD-L1 expression with clinical parameters and laboratory data were analyzed.sPD-L1 was detected in 35 plasma samples, the mean sPD-L1 concentration was 45.47 pg/ml. sPD-L1 was significantly higher in stage III-IVa (50.76 ± 28.15 pg/ml) compared to stage I-II (19.87 ± 11.38 pg/ml) (t = 2.618, P = .013). sPD-L1 was also higher in stage N2-3 (52.03 ± 28.98 pg/ml) than that in N0-1 (32.88 ± 23.75 pg/ml) (t = 2.096, P = .046). Univariate analysis identified that sPD-L1 level positively correlated with clinical stage (r = 0.495, P = .002) and N stage (r = 0.34, P = .046). Multivariate analysis showed the clinical stage was an independent factor affecting sPD-L1 expression.This is the first report to detect sPD-L1 in NPC. The study indicated sPD-L1 is quantifiable, convenient and easy to obtain. sPD-L1 may serve as a useful biomarker for evaluating tumor progression and therapeutic efficacy of NPC.
据报道，可溶性程序性死亡受体配体1（sPD-L1）的血浆水平是许多恶性肿瘤的独立预后因素。鼻咽癌（NPC）中sPD-L1的表达尚未见报道。本研究旨在评估NPC患者中sPD-L1的表达，并分析其与临床特征的相关性。纳入35例I-IVa期NPC患者。在预处理时采集血浆样本。采用酶联免疫吸附测定（ELISA）法检测sPD-L1浓度。分析sPD-L1表达与临床参数和实验室数据的相关性。在35份血浆样本中检测到sPD-L1，sPD-L1平均浓度为45.47 pg/ml。与I-II期（19.87±11.38 pg/ml）相比，III-IVa期（50.76±28.15 pg/ml）的sPD-L1显著更高（t = 2.618，P = 0.013）。N2-3期（52.03±28.98 pg/ml）的sPD-L1也高于N0-1期（32.88±23.75 pg/ml）（t = 2.096，P = 0.046）。单因素分析发现sPD-L1水平与临床分期（r = 0.495，P = 0.002）和N分期（r = 0.34**，**P = 0.046）呈正相关。多因素分析显示临床分期是影响sPD-L1表达的独立因素。这是首次在NPC中检测sPD-L1的报告。该研究表明sPD-L1是可量化的，方便且易于获取。sPD-L1可能作为评估NPC肿瘤进展和治疗疗效的有用生物标志物。
